FORTIFI-FLEX
32 evidence topics · 10 sources
Objective
Study aim in the ClinicalTrials.gov record
Main and secondary objectives in the EU trial record
Location and study date
Study dates in the ClinicalTrials.gov record
| Study characteristic | Quoted record |
|---|---|
| Study start (estimated) | “2026-09” |
| Primary completion (estimated) | “2028-03” |
| Study completion (estimated) | “2029-03” |
| First posted | “2026-09-08” |
| Sites | “This study has 7 locations” |
Study design
Open-label randomized phase 2 design in the ClinicalTrials.gov record
Study design in the second-quarter results press release
Study schema in the corporate presentation
Eligibility criteria
Exclusion criteria in the ClinicalTrials.gov record
HPV status determination in the EU trial record
Prior-therapy criteria in the EU trial record
Measurable disease and performance status in the EU trial record
Treatment
Treatment arms in the ClinicalTrials.gov record
Loading regimen for all participants in the ClinicalTrials.gov record
Study outcomes
Rationale for using progression-free survival rate in the maintenance phase as the primary endpoint
Primary endpoint in the ClinicalTrials.gov record
| Primary endpoint | Quoted record |
|---|---|
| Measure | “Proportion of participants in maintenance phase who are progression-free as assessed by blinded independent central review (BICR) per RECIST 1.1 and alive.” |
| Time frame | “Approximately 9 months.” |
Secondary endpoints in the ClinicalTrials.gov record
“Serum exposure of ficerafusp alfa.” (opens the source at this quote in a new tab)
“Overall Survival (OS)” (opens the source at this quote in a new tab)
“Time to maximum tumor shrinkage” (opens the source at this quote in a new tab)
“Incidence of ≥Grade 3 TEAEs” (opens the source at this quote in a new tab)
“Incidence of Serious adverse events (SAEs)” (opens the source at this quote in a new tab)
Deep response definition in the EU trial record
Regulatory basis for the alternate regimen in company documents
Basis in the every-two-week expansion cohort in the annual report
FDA dose-optimization guidance on activity endpoints for dosage comparisons
FDA endpoint guidance on progression-free survival
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment in the ClinicalTrials.gov record
Planned enrollment in the corporate presentation
Description of analysis sets
Maintenance-phase randomization in the ClinicalTrials.gov record
Maintenance-phase and overall-course analyses in the EU trial record
Results
Participant disposition
Enrollment status in the third-quarter results press release
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
FORTIFI-FLEX is open-label, with no masking. Randomization occurs only after the 12-week loading phase and includes only participants without progression, so the randomized comparison addresses maintenance dosing in that subset. Both arms receive ficerafusp alfa with pembrolizumab. The primary endpoint, the proportion of maintenance-phase participants alive and progression-free at approximately 9 months, is assessed by BICR. Planned enrollment is 160 participants, and no results have been reported.